

IN THE CLAIMS:

Please add the following claims:

C

-- 31. A method for the treatment of an autoimmune disease or graft-versus-host reaction in a patient, comprising administering to said patient an effective amount of at least one protein selected from the group consisting of proteins having an amino acid sequence substantially corresponding to that of the binding site of the cell surface TNF receptors types I and II and that have the same ability to bind to TNF as natural or recombinant Tumor Necrosis Factor Binding Protein I (TBP-I) or Tumor Necrosis Factor Binding Protein II (TBP-II).

32. A method according to claim 31, wherein said protein is a combination of a protein substantially corresponding to TBP-I and a protein substantially corresponding to TBP-II.

33. A method according to claim 31 for the treatment of rheumatoid arthritis.

34. A method according to claim 31 for the treatment of graft-versus-host reactions.

35. A method for the treatment of an autoimmune disease or graft-versus-host reaction in a patient, comprising administering to said patient an effective amount of at least one protein selected from the group consisting of proteins having an amino acid sequence substantially corresponding to that of natural or

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000

recombinant TBP-I and TBP-II and that have the same ability to bind to TNF as natural or recombinant TBP-I or TBP-II.

36. A method for the treatment of an autoimmune disease or graft-versus-host reaction in a patient, comprising administering to said patient an effective amount of a polypeptide selected from the group consisting of polypeptides having an amino acid sequence substantially corresponding to that of the binding site of the cell surface TNF receptors types I and II, and having an amino acid sequence substantially corresponding to that of recombinant TNF binding protein having the amino acid sequence set forth in claim 19, and that has the same ability to bind to TNF as the TNF binding protein having the amino acid sequence set forth in claim 19.

37. A method according to claim 36 for the treatment of rheumatoid arthritis.

38. A method according to claim 36 for the treatment of graft-versus-host reactions.

39. A method for the treatment of an autoimmune disease or graft-versus-host reaction in a patient, comprising administering to said patient an effective amount of a polypeptide having an amino acid sequence substantially corresponding to that of recombinant TNF binding protein set forth in claim 19 and that has

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000